Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

BTK Biological Pathways Reviews

Videos

John Allan, MD
Videos
08/18/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
At the 2023 Great Debates &...
08/18/2023
Oncology
Susan M. O'Brien, MD
Videos
08/17/2023
Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Susan M. O'Brien, MD, discusses...
08/17/2023
Oncology
Ryan Jacobs, MD
Videos
12/13/2022
Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...
Ryan Jacobs, MD, discusses findings from a real-world analysis exploring BTK inhibitor-class switching in the first-line treatment of CLL and SLL, suggesting approximately 40% of patients who switch from ibrutinib to acalabrutinib experience...
Ryan Jacobs, MD, discusses...
12/13/2022
Oncology
Dr Shadman
Videos
01/10/2022
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle Cancer Care Alliance, highlights phase 2 Study of zanubrutinib in BTK Inhibitor-Intolerant patients with relapsed/refractory B-Cell malignancies, presented at the 2021 ASH Annual Meeting.
Mayzar Shadman, MD, MPH, Seattle...
01/10/2022
Oncology
Michael Wang, MD, Talks LOXO-305 for MCL, WM
Videos
12/07/2020
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
In this video, Dr Wang discusses...
12/07/2020
Oncology
Expert Roundtable
Videos
11/07/2024
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert...
11/07/2024
Oncology
Expert Roundtable
Videos
11/07/2024
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert...
11/07/2024
Oncology
Videos
11/05/2024
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of...
11/05/2024
Oncology
John Leonard, MD
Videos
11/05/2024
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
11/05/2024
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
11/05/2024
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
11/05/2024
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
Jonathan Riess, MD
Conference Coverage
10/31/2024
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses...
10/31/2024
Oncology
Elisabeth Livingstone, MD
Conference Coverage
10/31/2024
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD,...
10/31/2024
Oncology
Andrea Botticelli, MD
Conference Coverage
10/31/2024
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD,...
10/31/2024
Oncology
OLN

BTK

ALIASES

Bruton’s tyrosine kinase

Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, plays an important role in B-cell receptor activation.1 BCR activation results in translocation and phosphorylation of BTK. When BTK is inducted it activates phospholipase C and calcium mobilization, which results in downstream events, including proliferation, maturation, differentiation, and survival.2

Understanding the Role of BTK

Resources

News
11/28/2023
BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.
BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.
BTK inhibitor ibrutinib...
11/28/2023
Oncology
News
11/03/2023
A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...
A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...
A regimen consisting of...
11/03/2023
Oncology
News
09/27/2023
BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.
BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.
BTK inhibitor zanubrutinib...
09/27/2023
Oncology
News
09/21/2023
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that...
09/21/2023
Oncology
News
09/01/2023
BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.
BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.
BTK inhibitor ibrutinib plus...
09/01/2023
Oncology
News
08/02/2023
Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.
Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.
Patients with high BCL2/MYC...
08/02/2023
Oncology
News
07/17/2023
According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.
According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.
According to a phase 2 trial,...
07/17/2023
Oncology
News
06/08/2023
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
06/06/2023
A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.
A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.
A phase 3 trial indicated that...
06/06/2023
Oncology
News
05/01/2023
Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.
Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.
Findings from a multicenter...
05/01/2023
Oncology
News
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Podcasts

Episode 2: BTK Inhibitors for CLL and Lymphomas
Podcasts
07/03/2020
On this episode of Blood Bytes, John Leonard, MD, and Richard Furman, MD, discuss BTK inhibitors for the treatment of CLL and lymphomas.
On this episode of Blood Bytes, John Leonard, MD, and Richard Furman, MD, discuss BTK inhibitors for the treatment of CLL and lymphomas.
On this episode of Blood Bytes,...
07/03/2020
Oncology
BTK Inhibitors Important in the Treatment Landscape of MCL
Podcasts
01/23/2020
Michael Wang, MD, discusses the importance of BTK inhibitors for the treatment of patients with MCL.
Michael Wang, MD, discusses the importance of BTK inhibitors for the treatment of patients with MCL.
Michael Wang, MD, discusses the...
01/23/2020
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Interactive

Quiz
09/01/2023
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the...
09/01/2023
Oncology
Quiz
05/08/2023
In a study assessing the efficacy and safety of BTK inhibitor DTRMWXHS-12 plus everolimus and pomalidomide among 32 patients with hematologic malignancies, how many patients were highly responsive to this treatment?
In a study assessing the efficacy and safety of BTK inhibitor DTRMWXHS-12 plus everolimus and pomalidomide among 32 patients with hematologic malignancies, how many patients were highly responsive to this treatment?
In a study assessing the...
05/08/2023
Oncology
Quiz
02/27/2023
True or False: According to a phase 3 study, zanubritinib treatment for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia yielded superior progression free survival and overall remission rates when...
True or False: According to a phase 3 study, zanubritinib treatment for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia yielded superior progression free survival and overall remission rates when...
True or False: According to a...
02/27/2023
Oncology
Quiz
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
Quiz
11/06/2024
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene...
11/06/2024
Oncology
Quiz
10/16/2024
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to...
10/16/2024
Oncology
Quiz
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
10/11/2024
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to...
10/11/2024
Oncology
Quiz
10/11/2024
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented...
10/11/2024
Oncology
Quiz
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
10/08/2024
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an...
10/08/2024
Oncology
Quiz
10/03/2024
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811...
10/03/2024
Oncology
Quiz
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement